COMMUNIQUÉS West-GlobeNewswire

Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism
29/07/2019
SAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for [...]
Alkahest Phase 2a Study AKST4290-202 in Refractory Neovascular AMD meets Primary and Secondary Endpoints
29/07/2019
SAN CARLOS, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, announced that its phase 2a [...]
Arbutus to Report Second Quarter 2019 Financial Results
29/07/2019
WARMINSTER, Pa., July 29, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its [...]
Plus Therapeutics, Inc. Announces Nasdaq Ticker Symbol Changes and Reverse Stock Split
29/07/2019
AUSTIN, Texas, July 29, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that the Company has officially changed its name from “Cytori Therapeutics, Inc.” to “Plus [...]
Radient Technologies Inc. Issues Shares For Services
29/07/2019
EDMONTON, Alberta, July 29, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI; OTCQX: RDDTF ) has issued an aggregate of 93,151 common shares to a third party consultant [...]
Unum Therapeutics Announces New Appointments to its Board of Directors
29/07/2019
CAMBRIDGE, Mass., July 29, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its [...]
Axogen, Inc. to Participate at Canaccord Genuity 39th Annual Growth Conference
29/07/2019
ALACHUA, Fla., July 29, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced [...]
Akcea Therapeutics to Hold Second Quarter 2019 Financial Results Webcast
29/07/2019
Webcast scheduled for Tuesday, August 6th at 4:30 p.m. Eastern Time BOSTON, July 29, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it [...]
Avadel Pharmaceuticals to Report Second Quarter 2019 Financial Results
29/07/2019
DUBLIN, Ireland, July 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that it will host a conference call and live webcast [...]
Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome
29/07/2019
NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]
Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer
29/07/2019
NEW HAVEN, Conn., July 29, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today the appointment of Ronald [...]
Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer
29/07/2019
CARMIEL, Israel, July 29, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that Eyal Rubin has been appointed to serve as the Company’s new Senior Vice President and [...]
European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10
29/07/2019
Access based on positive interim analysis of clinical data as well as preclinical data to date PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at supporting accelerated [...]
Amicus Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019
29/07/2019
CRANBURY, N.J., July 29, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2019 at 8:30 a.m. ET to [...]
Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility
29/07/2019
Extends interest-only period and time to access additional funding NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel [...]
Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by 56%
29/07/2019
Potential First-in-Class Treatment VANCOUVER, British Columbia, July 29, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”), a clinical [...]
Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin
29/07/2019
Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections Global Phase 3 [...]
Stemline Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results on August 2, 2019
29/07/2019
NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, [...]
Novo Nordisk A/S – Share repurchase programme
29/07/2019
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 29 July 2019 – On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European [...]

Pages